David Johnson appointed to Caribou board; brings 30 years biopharma commercial experience

Caribou Biosciences, Inc.

Board expanded from 7 to 8 directors; Johnson appointed effective May 11, 2022.
Annual cash compensation of $40,000; initial option for 44,000 shares vesting over 3 years.
Johnson was CCO at Global Blood Therapeutics and spent 15 years at Gilead in commercial roles.
No immediate committee assignments; standard indemnification agreement entered.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David L. Johnson

Class II director

CRBU · Caribou Biosciences, Inc.

Effective: 2022-05-11
Filed: May 11, 2022, 7:59 PM ET

increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David L. Johnson was appointed as Class II director at Caribou Biosciences, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.

View on SEC.gov

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-009315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.